---
title: "Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/266416790.md"
description: "Emily Bodnar from H.C. Wainwright maintains a Buy rating on Olema Pharmaceuticals, raising the price target to $36.00, due to promising trial data for palazestrant in breast cancer treatment. The positive interim data from Roche’s lidERA trial boosts confidence in palazestrant's efficacy. J.P. Morgan also maintains a Buy rating with a $32.00 target, highlighting significant market opportunities for Olema."
datetime: "2025-11-18T16:35:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266416790.md)
  - [en](https://longbridge.com/en/news/266416790.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266416790.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/266416790.md) | [English](https://longbridge.com/en/news/266416790.md)


# Positive Outlook on Olema Pharmaceuticals’ Palazestrant Driven by Promising Trial Data and Market Potential

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals. The associated price target was raised to $36.00.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Emily Bodnar’s rating is based on the promising potential of Olema Pharmaceuticals’ palazestrant in the treatment of ER+/HER2- breast cancer. The recent positive interim data from Roche’s lidERA trial, which evaluated giredestrant, another oral SERD, has increased confidence in the efficacy of palazestrant. The lidERA trial demonstrated statistically significant benefits in invasive disease-free survival, suggesting that oral SERDs could play a crucial role in breast cancer treatment.  
Given the success of giredestrant, Bodnar anticipates that Olema’s ongoing Phase 3 trial of palazestrant in combination with ribociclib for 1L metastatic breast cancer could yield similarly positive results. This trial could potentially replace the current AI backbone with an oral SERD, offering a significant market opportunity, especially in the adjuvant setting where patients may remain on therapy for extended periods. The potential for palazestrant to expand into the adjuvant setting further supports the Buy rating, as it indicates a substantial upside in market opportunity.

In another report released today, J.P. Morgan also maintained a Buy rating on the stock with a $32.00 price target.

### 相關股票

- [Olema Pharmaceuticals (OLMA.US)](https://longbridge.com/zh-HK/quote/OLMA.US.md)

## 相關資訊與研究

- [Meet 'Dobby': The AI agent that could kill the app economy](https://longbridge.com/zh-HK/news/281354277.md)
- [SharonAI Secures Major Long-Term AI Cloud Services Deal](https://longbridge.com/zh-HK/news/281363534.md)
- [Realbotix to Deliver 19 AI Humanoid Robots as It Scales Production](https://longbridge.com/zh-HK/news/281387250.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/zh-HK/news/281311983.md)
- [Is This the One ETF to Rule Them All?](https://longbridge.com/zh-HK/news/280916559.md)